ReviewEuropean radiology experimental2026
Beyond radiotheranostics: how imaging modality defines theranostics.
Review in European radiology experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Theranostics integrates diagnostic imaging and therapy within a single platform, enabling image-guided treatment delivery, real-time monitoring, and therapeutic optimization. The choice of imaging modality fundamentally shapes the design, functionality, and clinical maturity of theranostic systems. This review examines the theranostic concept through the lens of major imaging modalities employed in clinical and preclinical practice, including positron emission tomography (PET), single-photon emission computed tomography (SPECT), ultrasound (US), optical imaging (OI), magnetic resonance imaging (MRI), and computed tomography (CT). Beyond modality-specific approaches, the review highlights emerging multimodal theranostic strategies that integrate complementary imaging technologies to overcome individual limitations, enhance biological specificity, and improve treatment guidance. For each modality, we discuss the structural components of theranostic agents, their mechanisms of action, and the balance between diagnostic sensitivity and therapeutic efficacy. The review also highlights current and emerging clinical applications across major disease areas, while critically addressing limitations, such as spatial resolution, depth penetration, toxicity, and translational barriers. Overall, this article underscores that theranostics are expanding from modality-defined implementation toward integrated, multimodal strategies that are likely to shape the next generation of personalized and precision imaging-guided therapies. RELEVANCE STATEMENT : Imaging modality-driven theranostic design enables more precise, adaptive, and personalized image-guided therapies by aligning diagnostic sensitivity with therapeutic mechanisms, thereby improving treatment selection, response monitoring, and translational integration across clinical disciplines. KEY POINTS: Theranostics is determined by the underlying imaging modality rather than by a unified theranostic framework. Imaging modality dictates integration strategy. Nuclear medicine theranostics are clinically established, while MRI-, CT-, ultrasound-, and optical-based theranostics remain largely translational or function primarily as image-guided therapies. Multimodal theranostics address modality-specific limitations. Future progress depends on imaging-driven design and standardization.
Indexed as
Identifiers
42848292What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.